# Veno-venous ECMO for rapidly progressing interstitial lung disease: A multidisciplinary approach

## TL;DR

A rare case of rapidly progressing lung disease in a young man was successfully treated with a combination of immunosuppression, plasma exchange, and ECMO.

## Contribution

Highlights antisynthetase syndrome as a reversible cause of interstitial lung disease and the role of multidisciplinary decision-making in critical care.

## Key findings

- Antisynthetase syndrome can present as rapidly progressive interstitial lung disease requiring ICU intervention.
- Combination therapy with immunosuppression, plasma exchange, and V-V ECMO led to recovery in this case.
- Early recognition and aggressive treatment are crucial for managing such rare conditions.

## Abstract

This is a unique case of fulminant respiratory failure secondary to a rare cause of rapidly progressing ILD; antisynthetase syndrome (ASS). Failure to deliver timely multi-modal treatment in these cases can lead to increased morbidity and mortality.

A previously healthy 27-year-old male presented to his local hospital with a 1-week history of malaise, shortness of breath and cough. Initial work up including bloods and imaging were suggestive of community acquired multi lobar pneumonia, for which he received treatment as per local guidelines. Unfortunately, despite broad empirical antimicrobial cover, he continued to deteriorate with worsening type-1 respiratory failure requiring intubation and subsequent institution of prone position ventilation. Extensive microbiological investigations yielded no positive results. On day 7 of admission immunological testing revealed an ENA screen positive for Jo-1 antibody and a diagnosis of ASS was made. Despite treatment with immunosuppression the patient’s condition rapidly deteriorated and the decision to support with V-V ECMO was made following MDT consideration as there remained uncertainty as to the extent of reversibility of the underlying condition.

This patient recovered with combination of conventional immunosuppression, therapeutic plasma exchange and ECMO support. This case highlights Antisynthetase syndrome as a cause of reversible interstitial lung disease in the ICU and the importance of multi-disciplinary decision making and aggressive treatment approach in the management of such conditions.